The impact of smoking cessation on objective and subjective markers of sleep: review, synthesis, and recommendations.
Sleep disturbance is commonly reported as a prominent subjective symptom by quitting smokers. However, little research on this issue has used objective measures of sleep quality. Previous research has relied mainly on retrospective report of sleep disturbance, with few studies investigating sleep during the initial period after quitting tobacco use. Studies that have used objective measurements suggest that sleep fragmentation is a common occurrence during the withdrawal period. In sleep medicine, sleep disturbance is viewed as a consequence of frequent arousals and is now considered to have particularly deleterious daytime consequences, including sleepiness and dysphoric mood. Recent work also indicates that such awakenings affect the cardiovascular system by providing repetitive bursts of sympathetic nervous system activation, possibly contributing to elevated levels of cardiovascular and cerebrovascular morbidity. Pharmacological treatments designed to facilitate smoking cessation are ineffective for sustained abstinence in many smokers, which may be related to sleep disturbance. Indeed, preliminary evidence suggests that the administration of nicotine replacement therapy (NRT) or bupropion can result in disrupted sleep, particularly in women. However, to better understand the role that nicotine withdrawal and bupropion or NRT treatment, independently and in combination, might play in sleep disturbance, it is necessary to develop a better understanding of the nature of the sleep disturbance than can be provided by self-report. This is particularly important for the development of treatment approaches targeted to ameliorate sleep disruption as part of an overall smoking cessation strategy. The present review seeks to report the current state of knowledge based on extant findings and argues for the need to conduct more detailed polysomnographic investigations of the potentially vicious cycle of smoking cessation leading to sleep disturbances that may prove iatrogenic to sustained cessation.
Colrain
Ian M
IM
Human Sleep Research Program, SRI International, Menlo Park, CA 94025, USA. ian.colrain@sri.com
Trinder
John
J
Swan
Gary E
GE
D000279:Administration, Cutaneous; D001143:Arousal / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D016642:Bupropion / Q000627:therapeutic use; D002940:Circadian Rhythm; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use; D004333:Drug Administration Routes; D004569:Electroencephalography; D005731:Ganglionic Stimulants / Q000494:pharmacology / Q000627:therapeutic use; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D009538:Nicotine / Q000494:pharmacology / Q000627:therapeutic use; D012892:Sleep Deprivation / Q000453:epidemiology; D012895:Sleep, REM / Q000502:physiology*; D016540:Smoking Cessation / Q000379:methods*; D013564:Sympathetic Nervous System / Q000187:drug effects; D014029:Tobacco Use Disorder / Q000188:drug therapy* / Q000453:epidemiology; D014630:Vagus Nerve / Q000187:drug effects
D018765:Dopamine Uptake Inhibitors; D005731:Ganglionic Stimulants; D016642:Bupropion; D009538:Nicotine